Microfluidics Market by Product (Devices, Components (Chip, Sensor, Pump, Valve)), Application (IVD (POC, Clinical, Veterinary), Research, Manufacturing, Therapeutics), End User (Hospital, Diagnostic Center, Academic Institutes) - Global Forecast to 2026
[335 Pages Report] The global microfluidics market is projected to reach USD 58.8 billion by 2026 from USD 20.7 billion in 2021, growing at a CAGR of 23.2% during the forecast period. Microfluidic technologies offer quick analysis, reduced reagent consumption, and accurate test results and help in reducing the overall cost of the drug development process. In addition to these factors, the demand for microfluidics technology is increasing owing to the growing demand and adoption of PoC diagnostic devices, such as glucose monitoring and pregnancy test kits.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 Impact on Microfluidics Market
The COVID-19 pandemic has impacted the overall microfluidics industry in positive ways. The demand for rapid diagnostic tests, POC tests, and IVD devices with microfluidic technology utilized in drug discovery and COVID-19 testing has witnessed a significant demand. Several industry players are focusing on introducing rapid antigen tests based on microfluidics technology to detect COVID-19. Regulatory authorities also have extended support to approve microfluidics tests to combat the pandemic. Thus, the microfluidics industry has experienced positively as well as negative effects, and key players have undertaken strategic decisions to cope with the situation. The increasing number of rapid diagnostic tests, POC tests, and IVD devices also increase the demand for microfluidics kits to ensure the accuracy and precision of patients’ sample results.
Microfluidics Market Dynamics
Driver: Rising demand for point-of-care testing
The global PoC diagnostics market is expected to showcase lucrative growth potential (~10%) in the coming years. This growth is largely due to the rising prevalence of lifestyle-related and infectious diseases and the increasing preference for home healthcare. In addition, growing private investments and venture funding for the development of new products, coupled with government support for improving the adoption of PoC devices, are supporting the growth of the PoC diagnostics market. The rising incidence and prevalence of various diseases, coupled with product miniaturization and decentralization of healthcare, are the major factors that are expected to offer significant growth opportunities to players operating in the PoC diagnostics market.
Restraint: Complex and time-consuming regulatory approval process
Manufacturers of medical devices are required to comply with stringent regulatory policies to ensure the marketing and sales of their products in global markets. The US is a major manufacturing hub for microfluidic devices as a majority of the leading global players are based in the country. In the US, the FDA has set stringent regulatory standards and guidelines to ensure the safety and efficacy of medical devices. However, over the last few years, the FDA approval process for medical devices has become a lengthy and complex process. This is a major challenge faced by companies while launching new and innovative products in the US. For instance, the average approval time for a 510(K) application increased to 151 days during 2011–15, which was 96 days from 2001–05. This is expected to have a major impact on the drug delivery, pharmaceutical, and IVD industries. Furthermore, during the approval process, it is not certain whether the product will receive approval or the terms of approval may have a negative impact on the profitability of the product. Any enforcement action by governments also results in negative publicity, which impacts the market adversely.
Opportunity: Emergence of microfluidic-based 3D cell culture systems
Organ-on-a-chip systems can be used to study many biomedical phenomena in drug development and toxicity testing as well as in personalized medicine (where stems cells derived from individual patients can be used to identify which therapies are likely to succeed). Recent advances have enabled the use of microfluidics in 3D cell culture to develop microenvironments that support tissue differentiation and replicate the tissue-tissue interface, spatiotemporal chemical gradients, and mechanical microenvironments of living organs. Organ-on-a-chip models enable the study of human physiology in an organ-specific context, which allows the development of in vitro disease models and eventually serves as a replacement for animal models in drug development and toxicity testing. Given its potential, a number of research studies are being conducted to evaluate the performance of microfluidic chips in pharmaceutical studies.
Challenge: Standardization/ commercialization of microfluidic devices
Customer acceptance and market adoption are the two major factors that affect the commercialization of any product or technology in the market. There are many academic publications of proof-of-concept for microfluidic technology-embedded medical devices and equipment, but the incorporation of this technology in end-use products has been limited over the last decade owing to the lack of standardized microfluidic devices that can be used by multiple end users. Despite the fact that microfluidics is a promising laboratory tool and is used in some applications, the technology is still not widely adopted in major applications in the life sciences and medical device industries. In addition, investors and venture capitalists are more interested in investing their funds in projects or products that give them faster returns on investment. As a result, researchers are forced to redirect their focus from innovative technologies such as microfluidics to other marketable products.
North America is expected to account for the largest share of the microfluidics market in 2020
In 2020, North America accounted for the largest share—41.7%—of the global microfluidics market, followed by Europe, the Asia Pacific, and Latin America. North America has various additional advantages—investment initiatives by governments and the presence of high-quality infrastructure for clinical and laboratory research. The growth in the market can be attributed to increasing R&D activities, rising government funding for drug discovery research, and high growth in the pharmaceutical and biotechnological industries.
To know about the assumptions considered for the study, download the pdf brochure
Key Market Players
The prominent players in the microfluidics market are Parker Hannifin Corporation (US), SMC Corporation (Japan), IDEXX Corporation (US), Fluigent SA (France), Aignep S.P.A. (Italy), Camozzi Automation SPA Societá Unipersonale (Italy), Dolomite microfluidics (UK), Elveflow (France), Cellix Limited (Ireland), Fortive Corporation (US), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Perkinelmer, Inc. (US), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Illumina Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Fluidigm Corporation (US) and Abbott Laboratories (US).
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market size available for years |
2019–2026 |
|
Base year considered |
2020 |
|
Forecast period |
2021–2026 |
|
Forecast units |
Value (USD) |
|
Segments covered |
By Product type, application and end user |
|
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa |
|
Companies covered |
Parker Hannifin Corporation (US), SMC Corporation (Japan), IDEXX Corporation (US), Fluigent SA (France), Aignep S.P.A. (Italy), Camozzi Automation SPA Societá Unipersonale (Italy), Dolomite microfluidics (UK), Elveflow (France), Cellix Limited (Ireland), Fortive Corporation (US), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Perkinelmer, Inc. (US), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Illumina Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Fluidigm Corporation (US) and Abbott Laboratories (US). |
The study categorizes the Microfluidics market based on product type, application, end user and regional & global level.
Global microfluidics market, by Product Type
- Microfluidic-based devices
- Microfluidic Components
- Microfluidic Chips
- Flow & Pressure Sensors
- Flow & Pressure Controllers
- Microfluidic Valves
- Micropumps
- Microneedles
- Other Components
Global microfluidics market, by Application
- In-vitro Diagnostics
- Clinical Diagnostics
- Point-of-care Testing
- Veterinary Diagnostics
- Pharmaceutical & Life Science Research and Manufacturing
- Lab Analytics
- Proteomics
- Genomics
- Cell-based Assays
- Capillary Electrophoresis
- Microdispensing
- Microreaction
- Lab Analytics
- Therapeutics
- Drug delivery
- Wearable devices
Global microfluidics market, by End User
- Hospitals & Diagnostic Centers
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
Global microfluidics market, by Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Southeast Asia
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Recent Developments
- In March 2020, Parker-Hannifin Corporation (US) launched the LM-Pro linear motor proportional valves for the ventilators market.
- In March 2020, Bio-Rad Laboratories Inc. (US) launched the SARS CoV-2 Standard to support laboratory assay validation of COVID-19 testing Germitec S.A. (France) received approval for the UV reprocessor from the FDA in April 2019.
- In July 2018, IDEXX Corporation (US) acquired Velcora Holding AB (Sweden). This acquisition helped the company strengthen its foothold in the microfluidics market on a global scale.
Frequently Asked Questions (FAQ):
Which are the top industry players in the microfluidics market?
The prominent players in the microfluidics market are Parker Hannifin Corporation (US), SMC Corporation (Japan), IDEX Corporation (US), Fluigent SA (France), Aignep S.P.A. (Italy), Camozzi Automation SPA Societá Unipersonale (Italy), Dolomite microfluidics (UK), Elveflow (France), Cellix Limited (Ireland), Fortive Corporation (US), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Perkinelmer, Inc. (US), Agilent Technologies, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Illumina Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Fluidigm Corporation (US) and Abbott Laboratories (US).
Which geographical region is growing at the highest rate in the microfluidics market?
APAC is estimated to be growing at the highest CAGR of 25.5%. Countries such as Japan, China, India, South Korea, Taiwan, Australia, and Singapore in APAC are estimated to be the major contributors to the Asia Pacific microfluidics market. The rising geriatric population, growing per capita income, increasing investments in the healthcare industry by key market players, rising demand for advanced technologies, and expansion of private-sector hospitals to rural areas in various countries in the Asia Pacific are the major factors driving the growth of the microfluidics market in this region.
Which segment of product type is dominating the microfluidics market?
Based on product, the microfluidics market is broadly classified into microfluidic-based devices and microfluidic components. In 2020, the microfluidic-based devices segment accounted for the largest share (84.4%) of the microfluidics market by product. The large share of this segment can majorly be attributed to the increasing adoption of technologically advanced microfluidic-based devices in pharmaceutical & life science research, increasing need for miniaturization of laboratory equipment, growing demand for microfluidic-based PoC testing, and the increasing use of microfluidic technology for drug discovery.
Which is the leading application segment with the highest share in microfluidics market?
In this report, the microfluidics market is broadly classified into three major application segments—in vitro diagnostics, pharmaceutical & life science research and manufacturing, and therapeutics. The in vitro diagnostics segment accounted for the largest share of 60.0% of the microfluidics market in 2020. The large share of this segment is mainly attributed to the rising incidence of target diseases and the growing demand for PoC testing. The advantages of microfluidic devices over traditional devices (such as portability, compact size, increased frequency of testing, and accurate & quick analysis) have also driven the adoption of these devices in IVD applications.
Which is the highest growing end user segment in microfluidics market?
The microfluidics market is segmented into hospitals and diagnostic centers, academic & research institutes, and pharmaceutical & biotechnology companies based on end users. The hospitals and diagnostic centers segment accounted for the largest share of the end users market in 2020. Factors attributing to the large share of the segment include the increasing use of microfluidic-based diagnostic devices, increasing adoption of microfluidic technology for the rapid diagnosis of various chronic diseases, and rising technological advancements. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 27)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 33)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION: ABBOTT LABORATORIES
FIGURE 7 REVENUE ANALYSIS OF THE TOP FOUR COMPANIES: MICROFLUIDICS-BASED DEVICES MARKET (2020)
FIGURE 8 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MICROFLUIDICS MARKET (2021–2026)
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 10 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 MARKET DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: MICROFLUIDICS MARKET
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 48)
FIGURE 12 MICROFLUIDICS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 13 MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 14 MICROFLUIDICS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 15 MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 16 MICROFLUIDICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 17 GEOGRAPHIC ANALYSIS: GLOBAL MICROFLUIDICS MARKET
4 PREMIUM INSIGHTS (Page No. - 53)
4.1 GROWTH POTENTIAL OF THE MICROFLUIDICS MARKET
FIGURE 18 RISING DEMAND FOR POINT-OF-CARE TESTING IS A KEY FACTOR DRIVING THE GLOBAL MICROFLUIDICS MARKET
4.2 ASIA PACIFIC: MICROFLUIDICS MARKET, BY APPLICATION
FIGURE 19 CHINA ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MICROFLUIDICS MARKET IN 2020
4.3 MICROFLUIDICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 CHINA TO REGISTER THE HIGHEST GROWTH RATE IN THE MICROFLUIDICS MARKET DURING THE FORECAST PERIOD
4.4 MICROFLUIDICS MARKET, BY REGION
FIGURE 21 NORTH AMERICA TO DOMINATE THE GLOBAL MICROFLUIDICS MARKET DURING THE FORECAST PERIOD
4.5 MICROFLUIDICS MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 22 HIGH GROWTH OPPORTUNITIES IN BOTH DEVELOPING AND DEVELOPED MARKETS DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 57)
5.1 MARKET DYNAMICS
FIGURE 23 MICROFLUIDICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.1.1 MARKET DRIVERS
5.1.1.1 Rising demand for point-of-care testing
FIGURE 24 GLOBAL CANCER INCIDENCE, 2015–2040
5.1.1.2 Rising technological advancements
TABLE 2 SOME NEW PRODUCTS LAUNCHED BY MAJOR PLAYERS IN THE LAST THREE YEARS HAVE BEEN MENTIONED BELOW:
5.1.1.3 Increasing focus on data precision and accuracy
5.1.1.4 Highly economical
5.1.1.5 Rapid testing and improved portability through microfluidic chip miniaturization
TABLE 3 MARKET DRIVERS: IMPACT ANALYSIS
5.1.2 MARKET RESTRAINTS
5.1.2.1 Complex and time-consuming regulatory approval process
5.1.2.2 Incorporation of microfluidics into existing workflows
TABLE 4 MARKET RESTRAINTS: IMPACT ANALYSIS
5.1.3 MARKET OPPORTUNITIES
5.1.3.1 Emergence of microfluidic-based 3D cell culture systems
5.1.3.2 Asia─ a key growth market
5.1.3.3 Expanding applications of drug delivery technologies using microfluidics
5.1.3.4 Growing applications of microfluidics in the life sciences & pharmaceutical industries
TABLE 5 MARKET OPPORTUNITIES: IMPACT ANALYSIS
5.1.4 MARKET CHALLENGES
5.1.4.1 Standardization/commercialization of microfluidic devices
TABLE 6 MARKET CHALLENGES: IMPACT ANALYSIS
5.2 INDUSTRY TRENDS
5.2.1 SHIFTING TREND TOWARDS E-HEALTH DIAGNOSTICS WITH THE INTEGRATION OF MICROFLUIDICS-BASED POC DEVICES, EPIDERMAL ELECTRONICS, AND IOT
5.2.2 ADOPTION OF 3D PRINTING IN MICROFLUIDICS
5.2.3 SHIFTING TREND TOWARDS THE ADOPTION OF POLYMERS
5.2.4 UNIVERSITIES ACTIVELY INVESTING IN MICROFLUIDIC START-UPS
TABLE 7 LIST OF UNIVERSITY STARTUPS IN THE MICROFLUIDICS MARKET
5.3 VALUE CHAIN ANALYSIS
FIGURE 25 MICROFLUIDICS MARKET: VALUE CHAIN ANALYSIS
5.3.1 MICROFLUIDIC COMPONENTS PROCUREMENT MODEL OF MAJOR PLAYERS
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 26 MICROFLUIDICS MARKET: SUPPLY CHAIN ANALYSIS
5.5 ECOSYSTEM MARKET MAP
FIGURE 27 MICROFLUIDICS MARKET: ECOSYSTEM MARKET MAP
5.6 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT FROM NEW ENTRANTS
5.6.2 THREAT FROM SUBSTITUTES
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 BARGAINING POWER OF BUYERS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 REGULATORY ANALYSIS
5.7.1 NORTH AMERICA
5.7.1.1 US
TABLE 8 US: CLASSIFICATION OF MICROFLUIDICS TECHNOLOGY ASSOCIATED DIAGNOSTIC DEVICES
FIGURE 28 US: REGULATORY PROCESS FOR TESTING DEVICES ASSOCIATED WITH MICROFLUIDICS TECHNOLOGY
5.7.1.2 Canada
TABLE 9 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION
FIGURE 29 CANADA: REGULATORY PROCESS FOR MICROFLUIDICS ASSOCIATED IVD DEVICES IN CANADA
5.7.2 EUROPE
TABLE 10 EUROPE: CLASSIFICATION OF MICROFLUIDICS ASSOCIATED WITH IVD DEVICES
FIGURE 30 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
5.7.3 ASIA PACIFIC
5.7.3.1 Japan
TABLE 11 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION
5.7.3.2 China
TABLE 12 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION
5.7.3.3 India
FIGURE 31 INDIA: REGULATORY PROCESS FOR IVD DEVICES
5.8 IMPACT OF COVID-19 ON THE MICROFLUIDIC MARKET
FIGURE 32 THERMO FISHER SCIENTIFIC INC.: COVID-19 IMPACT ON SEGMENTAL ANALYSIS
FIGURE 33 ROCHE DIAGNOSTICS.: COVID-19 IMPACT ON SEGMENTAL ANALYSIS
FIGURE 34 BIO-RAD LABORATORIES, INC.: COVID-19 IMPACT ON SEGMENTAL ANALYSIS
FIGURE 35 ABBOTT LABORATORIES: COVID-19 IMPACT ON SEGMENTAL ANALYSIS
5.9 PATENT ANALYSIS
5.9.1 PATENT PUBLICATION TRENDS FOR MICROFLUIDICS
FIGURE 36 PATENT PUBLICATION TRENDS (2011–SEPTEMBER 2021)
5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 37 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR MICROFLUIDICS PATENTS (JANUARY 2011–SEPTEMBER 2021)
FIGURE 38 TOP APPLICANT COUNTRIES/REGIONS FOR MICROFLUIDICS PATENTS (JANUARY 2011–SEPTEMBER 2021)
5.1 TECHNOLOGY ANALYSIS
5.10.1 KEY TECHNOLOGIES
5.10.1.1 Biorecognition elements
5.10.1.2 Material science
5.10.1.3 Microfabrication
5.10.1.4 Direct-write
5.10.2 COMPLEMENTARY TECHNOLOGIES
5.10.2.1 MEMS
5.10.2.1.1 Micropumps
5.10.2.1.2 Microneedles
5.10.2.1.3 Microsensors/Transducers
5.10.3 ADJACENT TECHNOLOGIES
5.10.3.1 3D Printing
5.10.3.2 Lab-on-fiber
6 MICROFLUIDICS MARKET, BY PRODUCT (Page No. - 96)
6.1 INTRODUCTION
TABLE 13 MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 MICROFLUIDIC-BASED DEVICES
6.2.1 INCREASING ADOPTION OF MICROFLUIDIC DEVICES OWING TO THE VARIOUS ADVANTAGES OFFERED BY MICROFLUIDIC TECHNOLOGY TO DRIVE THE MARKET GROWTH
TABLE 14 MICROFLUIDIC-BASED DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 MICROFLUIDIC COMPONENTS
TABLE 15 MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 16 MICROFLUIDIC COMPONENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.1 MICROFLUIDIC CHIPS
6.3.1.1 Microfluidic chips reduce the analysis time by increasing automation
TABLE 17 MICROFLUIDIC CHIPS AVAILABLE IN THE MARKET
TABLE 18 MICROFLUIDIC CHIPS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.2 FLOW AND PRESSURE SENSORS
6.3.2.1 These devices offer advantages in cytometry and POCT, due to which they are increasingly used in laboratories and research institutes
TABLE 19 FLOW AND PRESSURE SENSORS AVAILABLE IN THE MARKET
TABLE 20 FLOW AND PRESSURE SENSORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.3 FLOW AND PRESSURE CONTROLLERS
6.3.3.1 Pressure controllers are sui TABLE as references for laboratories owing to their high accuracy and control stability
TABLE 21 FLOW AND PRESSURE CONTROLLERS AVAILABLE IN THE MARKET
TABLE 22 FLOW AND PRESSURE CONTROLLERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.4 MICROPUMPS
6.3.4.1 The need for precision in fluid control and device miniaturization supports the market growth for micropumps
TABLE 23 MICROPUMPS AVAILABLE IN THE MARKET
TABLE 24 MICROPUMPS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.5 MICROFLUIDIC VALVES
6.3.5.1 Valves are a vital component in microfluidic devices—a key factor driving the market growth
TABLE 25 MICROFLUIDIC VALVES AVAILABLE IN THE MARKET
TABLE 26 MICROFLUIDIC VALVES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.6 MICRONEEDLES
6.3.6.1 The small size of microneedles leaves dermal nerves and blood vessels unaffected, thus ensuring a painless procedure
TABLE 27 MICRONEEDLES AVAILABLE IN THE MARKET
TABLE 28 MICRONEEDLES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3.7 OTHER COMPONENTS
TABLE 29 OTHER MICROFLUIDIC COMPONENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 MICROFLUIDICS MARKET, BY APPLICATION (Page No. - 118)
7.1 INTRODUCTION
TABLE 30 MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
7.2 IN VITRO DIAGNOSTICS
TABLE 31 MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 32 MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
7.2.1 CLINICAL DIAGNOSTICS
7.2.1.1 Increase in viral outbreaks to drive growth in the clinical diagnostics segment
TABLE 33 MICROFLUIDICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
7.2.2 POINT-OF-CARE TESTING
7.2.2.1 Point-of-care testing is the second-largest application segment in the microfluidics market for in vitro diagnostics
TABLE 34 MICROFLUIDICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
7.2.3 VETERINARY DIAGNOSTICS
7.2.3.1 The growing need for low-cost, rapid, and reliable diagnostic results in veterinary medicine supports the market growth
TABLE 35 MICROFLUIDICS MARKET FOR VETERINARY DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING
FIGURE 39 LAB ANALYTICS ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING IN 202O
TABLE 36 MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 37 MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.1 LAB ANALYTICS
FIGURE 40 PROTEOMIC ANALYSIS TO DOMINATE THE LAB ANALYTICS MARKET DURING THE FORECAST PERIOD
TABLE 38 MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 39 MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.1.1 Proteomic analysis
7.3.1.1.1 Increasing demand for rapid proteomic analysis for drug development is propelling the demand for lab-on-a-chip devices
TABLE 40 MICROFLUIDICS MARKET FOR PROTEOMIC ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.1.2 Genomic analysis
7.3.1.2.1 Increasing focus on the decoding of genomes to boost the adoption of microfluidics in genomics
TABLE 41 MICROFLUIDICS MARKET FOR GENOMIC ANALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.1.3 Cell-based assays
7.3.1.3.1 Increasing focus on microfluidic cell-based assays for rapid drug development supports the market growth
TABLE 42 MICROFLUIDICS MARKET FOR CELL-BASED ASSAYS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.1.4 Capillary electrophoresis
7.3.1.4.1 Combination of microfluidic capillary electrophoresis with other technologies is expected to drive the overall market growth
TABLE 43 MICROFLUIDICS MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.2 MICRODISPENSING
7.3.2.1 Less sample and reagent consumption and the ease of operation to drive the adoption of microdispensing systems
TABLE 44 MICROFLUIDICS MARKET FOR MICRODISPENSING, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.3 MICROREACTION
7.3.3.1 The increasing need for optimization in the research and production process using microreaction technology supports market growth
TABLE 45 MICROFLUIDICS MARKET FOR MICROREACTION, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 THERAPEUTICS
FIGURE 41 DRUG DELIVERY APPLICATIONS TO DOMINATE THE THERAPEUTICS MARKET DURING THE FORECAST PERIOD
TABLE 46 MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 47 MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
7.4.1 DRUG DELIVERY
7.4.1.1 Expanding applications of microfluidics in the development of drug delivery platforms is a key factor driving the market growth
TABLE 48 MICROFLUIDICS MARKET FOR DRUG DELIVERY, BY COUNTRY, 2019–2026 (USD MILLION)
7.4.2 WEARABLE DEVICES
7.4.2.1 Increasing demand for microfluidics-integrated wearable devices for vital monitoring of patients to drive the segment growth
TABLE 49 MICROFLUIDICS MARKET FOR WEARABLE DEVICES, BY COUNTRY, 2019–2026 (USD MILLION)
8 MICROFLUIDICS MARKET, BY END USER (Page No. - 142)
8.1 INTRODUCTION
TABLE 50 MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
8.2 HOSPITALS AND DIAGNOSTIC CENTERS
8.2.1 HOSPITALS AND DIAGNOSTIC CENTERS ARE THE LARGEST END USERS OF MICROFLUIDIC TECHNOLOGIES
TABLE 51 MICROFLUIDICS MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 ACADEMIC & RESEARCH INSTITUTES
8.3.1 THE USE OF MICROFLUIDICS IN R&D IS EXPECTED TO INCREASE WITH GROWING FUNDING INITIATIVES IN LIFE SCIENCES
FIGURE 42 LIFE SCIENCE R&D SPENDING (2017–2019)
TABLE 52 MICROFLUIDICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.4.1 GROWING FOCUS ON LAUNCHING QUALITY DRUGS TO SUPPORT THE MARKET GROWTH FOR THIS END-USER SEGMENT
FIGURE 43 FDA APPROVALS FOR PERSONALIZED MEDICINE (2014–2020)
TABLE 53 MICROFLUIDICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
9 MICROFLUIDICS MARKET, BY REGION (Page No. - 150)
9.1 INTRODUCTION
FIGURE 44 MICROFLUIDICS MARKET: GEOGRAPHIC SNAPSHOT (2020)
TABLE 54 MICROFLUIDICS MARKET, BY REGION, 2019–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 45 NORTH AMERICA: MICROFLUIDICS MARKET SNAPSHOT
TABLE 55 NORTH AMERICA: MICROFLUIDICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 56 NORTH AMERICA: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 57 NORTH AMERICA: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 58 NORTH AMERICA: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 59 NORTH AMERICA: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 60 NORTH AMERICA: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 61 NORTH AMERICA: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 62 NORTH AMERICA: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 63 NORTH AMERICA: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2.1 US
9.2.1.1 The US dominates the microfluidics market in North America
TABLE 64 US: KEY MACROINDICATORS
TABLE 65 US: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 66 US: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 67 US: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 68 US: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 69 US: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 70 US: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 71 US: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 72 US: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Strong infrastructure and the availability of funding for biomedical research to support the market growth
TABLE 73 CANADA: KEY MACROINDICATORS
TABLE 74 CANADA: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 75 CANADA: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 76 CANADA: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 77 CANADA: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 78 CANADA: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 79 CANADA: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 CANADA: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 81 CANADA: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3 EUROPE
TABLE 82 EUROPE: MICROFLUIDICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 83 EUROPE: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 84 EUROPE: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 85 EUROPE: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 86 EUROPE: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 EUROPE: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 EUROPE: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 89 EUROPE: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 90 EUROPE: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Germany holds the largest share in the European market
TABLE 91 GERMANY: KEY MACROINDICATORS
TABLE 92 GERMANY: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 93 GERMANY: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 94 GERMANY: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 95 GERMANY: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 96 GERMANY: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 97 GERMANY: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 98 GERMANY: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 99 GERMANY: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.2 FRANCE
9.3.2.1 Genomics and proteomics research is strongly supported by the government of France
TABLE 100 FRANCE: KEY MACROINDICATORS
TABLE 101 FRANCE: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 102 FRANCE: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 103 FRANCE: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 104 FRANCE: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 FRANCE: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 106 FRANCE: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 107 FRANCE: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 108 FRANCE: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.3 UK
9.3.3.1 Increasing incidence of infectious diseases such as COVID-19 drives the growth of PoC testing and microfluidics
TABLE 109 UK: KEY MACROINDICATORS
TABLE 110 UK: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 111 UK: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 112 UK: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 113 UK: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 114 UK: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 115 UK: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 UK: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 UK: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Increasing demand for PoC testing aids market growth
TABLE 118 ITALY: KEY MACROINDICATORS
TABLE 119 ITALY: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 120 ITALY: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 ITALY: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 122 ITALY: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 123 ITALY: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 124 ITALY: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 125 ITALY: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 126 ITALY: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Increasing incidence of infectious and chronic diseases drives the growth of the market
TABLE 127 SPAIN: KEY MACROINDICATORS
TABLE 128 SPAIN: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 129 SPAIN: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 130 SPAIN: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 131 SPAIN: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 132 SPAIN: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 133 SPAIN: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 134 SPAIN: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 135 SPAIN: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.6 BENELUX
9.3.6.1 Increasing healthcare expenditure in Benelux to drive the growth of the microfluidics market
TABLE 136 BENELUX: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 137 BENELUX: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 138 BENELUX: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 139 BENELUX: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 140 BENELUX: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 141 BENELUX: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 142 BENELUX MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 143 BENELUX: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.7 REST OF EUROPE
TABLE 144 ROE: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 145 ROE: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 146 ROE: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 147 ROE: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 148 ROE: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 149 ROE: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 150 ROE: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 151 ROE: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 46 ASIA PACIFIC: MICROFLUIDICS MARKET SNAPSHOT
TABLE 152 ASIA PACIFIC: MICROFLUIDICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 153 ASIA PACIFIC: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 154 ASIA PACIFIC: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 155 ASIA PACIFIC: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 156 ASIA PACIFIC: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 157 ASIA PACIFIC: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 158 ASIA PACIFIC: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 159 ASIA PACIFIC: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 160 ASIA PACIFIC: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.1 CHINA
9.4.1.1 China holds a major share in the Asia Pacific microfluidics market
TABLE 161 CHINA: KEY MACROINDICATORS
TABLE 162 CHINA: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 163 CHINA: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 164 CHINA: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 165 CHINA: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 166 CHINA: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 167 CHINA: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 168 CHINA: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 169 CHINA: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Adoption of technologically advanced laboratory analytical instruments in research to drive market growth in Japan
TABLE 170 JAPAN: KEY MACROINDICATORS
TABLE 171 JAPAN: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 172 JAPAN: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 173 JAPAN: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 174 JAPAN: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 175 JAPAN: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 176 JAPAN: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 177 JAPAN: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 178 JAPAN: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Increasing pharma R&D and government funding in the biotechnology sector is a major factor driving the market growth in India
TABLE 179 INDIA: KEY MACROINDICATORS
TABLE 180 INDIA: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 181 INDIA: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 182 INDIA: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 183 INDIA: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 184 INDIA: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 185 INDIA: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 186 INDIA: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 187 INDIA: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.4 SOUTHEAST ASIA (SEA)
9.4.4.1 Growth in the market can be attributed to developing healthcare infrastructure and growing government support
FIGURE 47 HEALTHCARE EXPENDITURE (% GDP) IN SOUTHEAST ASIA (2018)
FIGURE 48 GERIATRIC POPULATION IN 2019 (% OF TOTAL POPULATION)
TABLE 188 SEA: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 189 SEA: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 190 SEA: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 191 SEA: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 192 SEA: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 193 SEA: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 194 SEA: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 SEA: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.5 REST OF ASIA PACIFIC
TABLE 196 ROAPAC: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 197 ROAPAC: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 198 ROAPAC: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 199 ROAPAC: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 200 ROAPAC: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 201 ROAPAC: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 202 ROAPAC: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 203 ROAPAC: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5 LATIN AMERICA
TABLE 204 LATIN AMERICA: MICROFLUIDICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 205 LATIN AMERICA: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 206 LATIN AMERICA: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 207 LATIN AMERICA: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 208 LATIN AMERICA: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 209 LATIN AMERICA: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 210 LATIN AMERICA: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 211 LATIN AMERICA: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 212 LATIN AMERICA: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.1 BRAZIL
9.5.1.1 Pharmaceutical & biologics QC to drive the market growth in Brazil
TABLE 213 BRAZIL: KEY MACROINDICATORS
TABLE 214 BRAZIL: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 215 BRAZIL: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 216 BRAZIL: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 217 BRAZIL: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 218 BRAZIL: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 219 BRAZIL: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 220 BRAZIL: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 221 BRAZIL: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.2 MEXICO
9.5.2.1 The rising prevalence of chronic diseases drives the growth of the microfluidics market in Mexico
TABLE 222 MEXICO: KEY MACROINDICATORS
TABLE 223 MEXICO: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 224 MEXICO: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 225 MEXICO: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 226 MEXICO: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 227 MEXICO: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 228 MEXICO: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 229 MEXICO: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 230 MEXICO: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.3 REST OF LATIN AMERICA (ROLATAM)
TABLE 231 ROLATAM: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 232 ROLA: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 233 ROLA: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 234 ROLA: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 235 ROLA: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 236 ROLA: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 237 ROLA: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 238 ROLA: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 THE MEA IS CONSIDERED A PROMISING REGION, ESPECIALLY FOR MICROFLUIDIC DRUG DELIVERY FIRMS
TABLE 239 MEA: MICROFLUIDICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 240 MEA: MICROFLUIDIC COMPONENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 241 MEA: MICROFLUIDICS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 242 MEA: MICROFLUIDICS MARKET FOR IN VITRO DIAGNOSTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 243 MEA: MICROFLUIDICS MARKET FOR PHARMACEUTICAL & LIFE SCIENCE RESEARCH AND MANUFACTURING, BY TYPE, 2019–2026 (USD MILLION)
TABLE 244 MEA: MICROFLUIDICS MARKET FOR LAB ANALYTICS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 245 MEA: MICROFLUIDICS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 246 MEA: MICROFLUIDICS MARKET, BY END USER, 2019–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 235)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 49 REVENUE ANALYSIS OF THE TOP PLAYERS IN THE MICROFLUIDICS-BASED DEVICE MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 50 MICROFLUIDICS-BASED DEVICES MARKET SHARE, BY KEY PLAYER, 2020
10.5 MARKET RANKING
TABLE 247 MICROFLUIDIC VALVES MARKET RANKING, BY KEY PLAYER, 2020
TABLE 248 MICROPUMPS MARKET RANKING, BY KEY PLAYER, 2020
10.6 COMPANY EVALUATION QUADRANT
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
FIGURE 51 MICROFLUIDICSMARKET: COMPANY EVALUATION QUADRANT (2020)
10.7 COMPANY EVALUATION QUADRANT FOR START-UPS
10.7.1 PROGRESSIVE COMPANIES
10.7.2 DYNAMIC COMPANIES
10.7.3 STARTING BLOCKS
10.7.4 RESPONSIVE COMPANIES
FIGURE 52 MICROFLUIDICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS (2020)
10.8 COMPANY PRODUCT FOOTPRINT
TABLE 249 PRODUCT PORTFOLIO ANALYSIS: MICROFLUIDICS MARKET
TABLE 250 APPLICATION PORTFOLIO ANALYSIS: MICROFLUIDICS MARKET
TABLE 251 END-USER PORTFOLIO ANALYSIS: MICROFLUIDICS MARKET
10.9 GEOGRAPHIC FOOTPRINT OF THE MAJOR PLAYERS IN THE MICROFLUIDICS MARKET
TABLE 252 GEOGRAPHIC REVENUE MIX: MICROFLUIDICS MARKET (2020)
10.10 COMPETITIVE SCENARIO
10.10.1 PRODUCT LAUNCHES
TABLE 253 PRODUCT LAUNCHES
10.10.2 DEALS
10.10.3 OTHER DEVELOPMENTS
TABLE 255 OTHER DEVELOPMENTS
11 COMPANY PROFILES (Page No. - 254)
11.1 KEY PLAYERS
(Business overview, Products offered, Recent Developments, MNM view)*
11.1.1 PARKER-HANNIFIN CORPORATION
TABLE 256 PARKER-HANNIFIN CORPORATION: BUSINESS OVERVIEW
FIGURE 53 PARKER-HANNIFIN CORPORATION: COMPANY SNAPSHOT (2020)
11.1.2 SMC CORPORATION
TABLE 257 SMC CORPORATION: BUSINESS OVERVIEW
FIGURE 54 SMC CORPORATION: COMPANY SNAPSHOT (2020)
11.1.3 IDEX CORPORATION
TABLE 258 IDEX CORPORATION: BUSINESS OVERVIEW
FIGURE 55 IDEX CORPORATION: COMPANY SNAPSHOT (2020)
11.1.4 FORTIVE CORPORATION
TABLE 259 FORTIVE CORPORATION: BUSINESS OVERVIEW
FIGURE 56 FORTIVE CORPORATION: COMPANY SNAPSHOT (2020)
11.1.5 DANAHER CORPORATION
TABLE 260 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
11.1.6 THERMO FISHER SCIENTIFIC INC.
TABLE 261 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 58 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2020)
11.1.7 PERKINELMER, INC.
TABLE 262 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 59 PERKINELMER, INC.: COMPANY SNAPSHOT (2020)
11.1.8 AGILENT TECHNOLOGIES, INC.
TABLE 263 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 60 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
11.1.9 BIO-RAD LABORATORIES, INC.
TABLE 264 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 61 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
11.1.10 BECTON, DICKINSON AND COMPANY
TABLE 265 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 62 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
11.1.11 ILLUMINA INC.
TABLE 266 ILLUMINA INC.: BUSINESS OVERVIEW
FIGURE 63 ILLUMINA INC.: COMPANY SNAPSHOT (2020)
11.1.12 FLUIGENT SA
TABLE 267 FLUIGENT SA: BUSINESS OVERVIEW
11.1.13 AIGNEP S.P.A.
TABLE 268 AIGNEP S.P.A.: BUSINESS OVERVIEW
11.1.14 F. HOFFMANN-LA ROCHE LTD.
TABLE 269 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 64 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
11.1.15 FLUIDIGM CORPORATION
TABLE 270 FLUIDIGM CORPORATION: BUSINESS OVERVIEW
FIGURE 65 FLUIDIGM CORPORATION: COMPANY SNAPSHOT (2020)
11.1.16 ABBOTT LABORATORIES
TABLE 271 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 66 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
11.1.17 CAMOZZI AUTOMATION SPA SOCIETÁ UNIPERSONALE
TABLE 272 CAMOZZI AUTOMATION SPA SOCIETA UNIPERSONALE : BUSINESS OVERVIEW
11.1.18 DOLOMITE MICROFLUIDICS
TABLE 273 DOLOMITE MICROFLUIDICS: BUSINESS OVERVIEW
11.1.19 ELVEFLOW
TABLE 274 ELVEFLOW: BUSINESS OVERVIEW
11.1.20 CELLIX LTD.
TABLE 275 CELLIX LTD. : BUSINESS OVERVIEW
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS
11.2.1 NANOSTRING
TABLE 276 NANOSTRING : COMPANY OVERVIEW
11.2.2 NORTIS INC.
TABLE 277 NORTIS INC. : COMPANY OVERVIEW
11.2.3 INNOVATIVE BIOCHIPS, LLC
TABLE 278 INNOVATIVE BIOCHIPS, LLC. : COMPANY OVERVIEW
11.2.4 FLUIDIC ANALYTICS
TABLE 279 FLUIDICS ANALYTICS : COMPANY OVERVIEW
11.2.5 EPIGEM INC.
TABLE 280 EPIGEM INC. : COMPANY OVERVIEW
12 APPENDIX (Page No. - 327)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
The global microfluidics market study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the microfluidics market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, industry experts from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Industry experts from the supply side include CEOs, vice presidents, marketing and sales directors, product managers, business development managers, technology and innovation directors of companies providing microfluidics, key opinion leaders, and suppliers and distributors. The industry experts from the demand side include hospitals, diagnostic centers, academic institutes, and research centers, as well as pharmaceutical and biotechnology companies.
Following the breakdown of primary respondents-
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and top-down approach (assessment of utilization/adoption/penetration trends, by product, application, end user, and region).
Data Triangulation
After arriving at the market size, the total microfluidics market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Objectives of the Study
- To define, describe, and forecast the global microfluidics market by product, application, end user, and region
- To provide detailed information about the factors influencing the market growth (drivers, restraints, opportunities, and challenges)
- To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the microfluidics market in five regions (along with major countries)—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
- To profile key players in the microfluidics market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions; new product launches; product approvals, and collaborations, partnerships, and agreements; of the leading players in the global microfluidics market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players
Geographic Analysis
- Further breakdown of the Rest of Asia Pacific microfluidics market into Australia, New Zealand, South Korea, Malaysia, and other countries
- Further breakdown of the Rest of Europe microfluidics market into Belgium, Russia, the Netherlands, Switzerland, and other countries
- Further breakdown of the Rest of Latin America microfluidics market into Argentina, Colombia, Chile, Ecuador, and others
Get in-depth analysis of the COVID-19 impact on the Microfluidics Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Microfluidics Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Microfluidics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Microfluidics Market